The main functions and efficacy of obeticholic acid drugs

Obeticholic acid(Obeticholic acid) is a semi-synthetic bile acid derivative. Its pharmacological action is based on activating the key nuclear receptor (Farnesoid X Receptor, FXR). FXR is mainly distributed in the liver and intestines and is a core regulatory factor regulating bile acid synthesis, metabolism, transport and cholesterol balance. By activating FXR, obeticholic acid can inhibit the excessive production of bile acids in the liver and promote its excretion and metabolism, thereby reducing hepatocellular toxicity, delaying inflammatory responses and the progression of fibrosis. This mechanism is highly targeted and cutting-edge for the treatment of cholestatic liver disease.

Obeticholic acid was originally developed and approved for the treatment of primary biliary cholangitis (PBC), especially in patients who have an inadequate response to or intolerance to ursodeoxycholic acid (UDCA). Clinical observations have found that obeticholic acid can not only effectively improve liver function indicators, such as alkaline phosphatase (ALP) and total bilirubin levels, but also delay liver fibrosis to a certain extent at the histological level. In addition to PBC, obeticholic acid also shows great potential in the field of other chronic liver diseases such as non-alcoholic steatohepatitis (NASH). NASH patients are often accompanied by hepatic fat deposition, inflammation, and fibrosis. The metabolic improvement effect regulated by the FXR pathway makes OCA one of the hottest drugs in global research on NASH treatment.

In addition, the metabolic characteristics of obeticholic acid make it have a relatively long half-life in the body, and its reuse through enterohepatic circulation helps maintain the stability of the therapeutic effect. The drug is primarily excreted through the bile and does not require significant dose adjustment in patients with renal insufficiency. It should be noted that obeticholic acid may cause adverse reactions such as itching, edema, and increased bilirubin during use, and should be carefully evaluated especially in patients with high doses or obvious liver damage.

Reference materials:https://en.wikipedia.org/wiki/Obeticholic_acid